Skip to main content

Table 10 Clinical data comparison of carriers versus non-carriers of MC1R variants

From: Some Molecular and Clinical Aspects of Genetic Predisposition to Malignant Melanoma and Tumours of Various Site of Origin

Feature Carriers (+)   Non-carriers (-) p (95% CI) OR
R160W
multiplicity1 3/852 (3.5%)   6/3743 (1.6%) n.s. 2.2
localization-skin4 2.45   1.3 n.s. 1.8
tumour type6 607/208/109/410   58/20/9/5 n.s.  
R151C
multiplicity 3/73 (4.1%)   7/402 (1.7%) n.s. 2.4
localization in skin 2.2   1.4 n.s. 1.5
tumour type 57/21/9/5   54/19/10/6 n.s.  
V60L
multiplicity 2/78 (2.6%)   6/355 (1.7%) n.s. 1.5
localization in skin 2.0   1.4 n.s. 1.4
tumour type 58/22/11/4   57/20/11/3 n.s.  
R163Q
multiplicity 1/30 (3.3%)   8/355 (2.2%) n.s. 1.5
localization in skin 1.9   1.5 n.s. 1.3
tumour type 60/19/10/5   58/18/9/5 n.s.  
  any of four variants positive   none of four variants positive   
multiplicity 8/254 (3.1%)   1/149 (0.7%) n.s. 4.8
localization in skin 2.2   1.0 0.0014 (1.35–3.63) 2.2
tumour type 61/21/8/5   60/20/9/4 n.s.  
  1. 1synchronic or metachronic tumours
  2. 2number of multiple melanoma cases/total number of MC1R variant carriers
  3. 3number of multiple melanoma cases/total number of patients without MC1R variants
  4. 4regions of exposed skin: head, nape, neck, forearms, palms, shanks, feet; regions of unexposed skin: trunk, thighs, arms, buttocks
  5. 5unexposed to exposed skin ratio – number of melanomas in unexposed skin divided by number of melanomas in exposed skin
  6. 6types of melanoma: a) SSM-superficial spreading melanoma; b) NM-nodular melanoma; c) LM-lentigo melanoma; d) ALM-acral lentigo melanoma
  7. 7 SSM percentage
  8. 8 NM percentage
  9. 9 LM percentage
  10. 10 ALM percentage